Feasibility and Safety of CT-Guided High-Dose-Rate Brachytherapy Combined with Transarterial Chemoembolization Using Irinotecan-Loaded Microspheres for the Treatment of Large, Unresectable Colorectal Liver Metastases

House, 2010, Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution, J Am Coll Surg, 210, 744, 10.1016/j.jamcollsurg.2009.12.040 Van Cutsem, 2016, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, 27, 1386, 10.1093/annonc/mdw235 Ruers, 2017, Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial, J Natl Cancer Inst, 109, 10.1093/jnci/djx015 Hackl, 2014, Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma, BMC Cancer, 14, 810, 10.1186/1471-2407-14-810 Nordlinger, 2013, Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial, Lancet Oncol, 14, 1208, 10.1016/S1470-2045(13)70447-9 Heinemann, 2014, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, Lancet Oncol, 15, 1065, 10.1016/S1470-2045(14)70330-4 Tol, 2009, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer, N Engl J Med, 360, 563, 10.1056/NEJMoa0808268 Cremolini, 2015, FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, Lancet Oncol, 16, 1306, 10.1016/S1470-2045(15)00122-9 Simkens, 2015, Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group, Lancet, 385, 1843, 10.1016/S0140-6736(14)62004-3 Shady, 2016, Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes–a 10-year experience at a single center, Radiology, 278, 601, 10.1148/radiol.2015142489 Sterzing, 2014, Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy, Strahlenther Onkol, 190, 872, 10.1007/s00066-014-0714-1 Collettini, 2014, Unresectable colorectal liver metastases: percutaneous ablation using CT-guided high-dose-rate brachytherapy (CT-HDBRT), Rofo, 186, 606, 10.1055/s-0033-1355887 Ricke, 2010, Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy, Int J Radiat Oncol Biol Phys, 78, 479, 10.1016/j.ijrobp.2009.09.026 Fiorentini, 2012, Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study, Anticancer Res, 32, 1387 Choy, 2001, Irinotecan and radiation in combined-modality therapy for solid tumors, Oncology (Williston Park, NY), 15, 22 Yokoyama, 2002, Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases, Cancer, 94, 1642, 10.1002/cncr.10422 Nanko, 1998, Micrometastatic colorectal cancer lesions in the liver, Surg Today, 28, 707, 10.1007/BF02484616 Seidensticker, 2010, Safety margin in irradiation of colorectal liver metastases: assessment of the control dose of micrometastases, Radiat Oncol, 5, 24, 10.1186/1748-717X-5-24 Gaba, 2016, Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria, J Vasc Interv Radiol, 27, 457, 10.1016/j.jvir.2015.12.752 2010 Ricke, 2004, (CT-Guided brachytherapy. A novel percutaneous technique for interstitial ablation of liver metastases), Strahlenther Onkol, 180, 274, 10.1007/s00066-004-1179-4 Ricke, 2010, MR-guided liver tumor ablation employing open high-field 1.0T MRI for image-guided brachytherapy, Eur Radiol, 20, 1985, 10.1007/s00330-010-1751-5 Fong, 1999, Surgical therapy of hepatic colorectal metastasis, Semin Oncol, 26, 514 Nordlinger, 1996, Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie, Cancer, 77, 1254, 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I Robertson, 2009, Survival after hepatic resection of colorectal cancer metastases: a national experience, Cancer, 115, 752, 10.1002/cncr.24081 Wei, 2006, Survival after hepatic resection for colorectal metastases: a 10-year experience, Ann Surg Oncol, 13, 668, 10.1245/ASO.2006.05.039 Small, 2007, Current controversies in the surgical management of colorectal cancer metastases to the liver, Isr Med Assoc J, 9, 742 Iezzi, 2015, Trans-arterial chemoembolization with irinotecan-loaded drug-eluting beads (DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a phase ii single-center study, Cardiovasc Intervent Radiol, 38, 1523, 10.1007/s00270-015-1080-9 Grothey, 2013, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 381, 303, 10.1016/S0140-6736(12)61900-X Iezzi, 2016, Combined locoregional treatment of patients with hepatocellular carcinoma: state of the art, World J Gastroenterol, 22, 1935, 10.3748/wjg.v22.i6.1935 Okuno, 2018, SN-38 acts as a radiosensitizer for colorectal cancer by inhibiting the radiation-induced up-regulation of HIF-1alpha, Anticancer Res, 38, 3323, 10.21873/anticanres.12598 Mauri, 2018, Transarterial embolization with small-size particles loaded with irinotecan for the treatment of colorectal liver metastases: results of the MIRACLE III Study, Cardiovasc Intervent Radiol, 41, 1708, 10.1007/s00270-018-2017-x Weiner, 2018, Predictors of survival after yttrium-90 radioembolization for colorectal cancer liver metastases, J Vasc Interv Radiol, 29, 1094, 10.1016/j.jvir.2018.02.020 Maleux, 2016, Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival, Acta Oncol, 55, 486, 10.3109/0284186X.2015.1101151